MTFB Motif Bio Plc

TIDMMTFB

RNS Number : 2402B

Motif Bio PLC

31 March 2017

31 March 2017

Motif Bio plc

("Motif Bio" or the "Company")

Change of Registered Office

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces a change in its registered office. With immediate effect, its new registered office is: 27/28 Eastcastle Street, London W1W 8DH.

For further information please contact:

 
 Motif Bio plc                                                  info@motifbio.com 
  Graham Lumsden (Chief 
  Executive Officer) 
 Zeus Capital Limited (NOMAD 
  & BROKER) 
  Phil Walker/Giles Balleny 
  Dominic Wilson                                              +44 (0)20 3829 5000 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/David 
  Hignell 
  John Howes/Rob Rees (Broking)                               +44 (0)20 3861 6600 
 Walbrook PR Ltd. (FINANCIAL       +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  PR & IR)                                               Mob: +44 (0)7980 541 893 
  Paul McManus                                           Mob: +44 (0)7900 608 002 
  Mike Wort 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                                               +49 (0)89 210 2280 
 

Notes to Editors:

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CROJBMATMBBJBIR

(END) Dow Jones Newswires

March 31, 2017 11:15 ET (15:15 GMT)

Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024

Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024